Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(1):CD003468.
doi: 10.1002/14651858.CD003468.

Amantadine in Parkinson's disease

N Crosby  1 , K H Deane, C E Clarke
Affiliations

Amantadine in Parkinson's disease

N Crosby et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: Although levodopa is the most common drug prescribed to relieve the symptoms of Parkinson's disease it is associated with motor and psychiatric side-effects. Consequently, interest has turned to alternative drugs with improved side-effect profiles to replace or augment levodopa. Amantadine, originally used as an antiviral drug, has been shown to improve the symptoms of Parkinson's disease.

Objectives: To compare the efficacy and safety of amantadine therapy (monotherapy or adjuvant therapy) versus placebo in treating people with Parkinson's disease.

Search strategy: Electronic searches of The Cochrane Controlled Trials Register (The Cochrane Library Issue 3, 2001), MEDLINE (1966-2001), EMBASE (1974-2001), SCISEARCH (1974-2001), BIOSIS (1993-2001), GEROLIT (1979-2001), OLDMEDLINE (1957-1965), LILACS (1982-2001), MedCarib (17th Century - 2001), PASCAL (1973-2001), JICST-EPLUS (1985-2001), RUSSMED (1973-2001), DISSERTATION ABSTRACTS (2000-2001), SIGLE (1980-2001), ISI-ISTP (1990-2001), Aslib Index to Theses (2001), Clinicaltrials.gov (2001), metaRegister of Controlled Trials (2001), NIDRR (2001) and NRR (2001) were conducted. Grey literature was hand searched and the reference lists of identified studies and reviews examined. The manufacturers of amantadine were contacted.

Selection criteria: Randomised controlled trials comparing amantadine with placebo in the treatment of patients with a clinical diagnosis of idiopathic Parkinson's disease.

Data collection and analysis: Data was abstracted independently by NC and KD onto standardised forms and disagreements were resolved by discussion.

Main results: Six randomised controlled trials were found comparing amantadine monotherapy or adjuvant therapy with placebo in the treatment of idiopathic Parkinson's disease. Five examined amantadine as adjuvant therapy with optimal levels of levodopa or anticholinergics and one examined amantadine as an adjuvant therapy with minimum tolerated levels of anticholinergics or as a monotherapy. Five were double-blind cross-over studies and one was a double-blind parallel group study. In total they examined 215 patients. The parallel group study allowed the randomisation codes to be broken and allowed patients in the placebo group to then receive amantadine. This could have led to bias. One study did not present the results of the placebo arm of the trial, hence we could not determine the difference between the two treatment groups. Two cross-over studies presented the results of the combined data from both treatment and placebo arms. The risk of carry-over effect into the second arm meant that these results could not be analysed. The final two studies presented at least some of their data from the end of the first arm of the trials. However only means were given, without standard deviations, so we could not determine the statistical significance of any difference between the amantadine and placebo groups. Although the authors did report on the side-effects from amantadine (such as livido recticularis, dry mouth and blurred vision), they state that none of them were severe.

Reviewer's conclusions: A considerable amount of evidence on the effectiveness of amantadine has accrued from non-controlled trials, often in patients with Parkinsonian conditions other than idiopathic Parkinson's disease. However, rigorous analysis of the six randomised controlled trials of amantadine reveals insufficient evidence of its efficacy and safety in the treatment of idiopathic Parkinson's disease.

PubMed Disclaimer

Conflict of interest statement

None.

References

References to studies included in this review

Fahn 1975 {published data only}
    1. Fahn S, Isgreen WP. Long‐term evaluation of amantadine and levodopa combination in parkinsonism by double‐blind crossover analyses. Neurology 1975;25:695‐700. - PubMed
Fehling 1973 {published data only}
    1. Fehling, C. The effect of adding amantadine to optimum l‐dopa dosage in Parkinson's syndrome. Acta Neurologica Scandinavica 1973;49:245‐251. - PubMed
Savery 1977 {published data only}
    1. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. Diseases of the Nervous System 1977;38(8):605‐608. - PubMed
Silver 1971 {published data only}
    1. Silver DE, Sahs AL. Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease. Transactions of the American Neurological Association 1971;96:307‐308. - PubMed
Walker 1972a {published data only}
    1. Walker JE, Albers JW, Tourtellotte WW, Henderson WG, Potvin AR, Smith A. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. Journal of Chronic Disease 1972;25:149‐182. - PubMed
Walker 1972b {published data only}
    1. Walker JE, Potvin A, Tourtellotte W, Albers J, Repa B, Henderson W, Snyder D. Amantadine and levodopa in the treatment of Parkinson's disease. Clinical Pharmacology and Therapeutics 1972;13(1):28‐36. - PubMed

References to studies excluded from this review

Appleton 1970 {published data only}
    1. Appleton DB, Eadie MJ, Sutherland JM. Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial. Medical Journal of Australia 1970;2(14):626‐629. - PubMed
Appleton 1971 {published data only}
    1. Appleton DB, Eadie MJ, Sutherland JM. The continued use of amantadine hydrochloride in parkinsonism. Medical Journal of Australia 1971;2(14):707‐709. - PubMed
Barbeau 1971 {published data only}
    1. Barbeau A, Mars H, Botez MI, Joubert M. Amantadine‐HCl (Symmetrel) in the management of Parkinson's disease: a double‐blind cross‐over study. Canadian Medical Association Journal 1971;105(1):42‐6. - PMC - PubMed
Bauer 1974 {published data only}
    1. Bauer RB, McHenry JT. Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology 1974;24(8):715‐720. - PubMed
Bodis‐Wollner 1997 {published data only}
    1. Bodis‐Wollner I, Francois J, Pantev M, Sogliocco A. Amantadine in the enrichment of treatment of Parkinson's disease patients. Movement Disorders 1997;12(Supplement 1):P360.
Boman 1970 {published data only}
    1. Boman K, Kivalo E, Porras J. Amantadine treatment in Parkinson's disease [Amantadinbehandling av parkinsonism]. Nordisk Medicin 1970;84(48):1518‐1520. - PubMed
    1. Boman K, Porras J. Amantadine treatment of Parkinson's disease. Acta Neurologica Scandinavica 1970;46(Supplement 43):225. - PubMed
Butzer 1975 {published data only}
    1. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease: a double‐blind, placebo‐controlled, crossover study with long‐term follow‐up. Neurology 1975;25:603‐606. - PubMed
Callaghan 1974a {published data only}
    1. Callaghan N, McIlroy M, O'Connor M. An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used in combination in Parkinson's disease. Irish Journal of Medical Science 1974;143(2):79‐85. - PubMed
Callaghan 1974b {published data only}
    1. Callaghan N, McLlroy M, O'Connor M. Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy. Irish Journal of Medical Science 1974;2:67‐78. - PubMed
Campbell 1972 {published data only}
    1. Campbell AM, Williams MJ. Trial of amantadine in Parkinson's disease. British Journal of Clinical Practice 1972;26(1):19‐22. - PubMed
Castaigne 1972 {published data only}
    1. Castaigne P, Laplane D, Dordain G. Amantadine: Prolonged clinical trial in 50 parkinsonian patients. Nouv Presse Med 1972;1(8):533‐536. - PubMed
Dallos 1970 {published data only}
    1. Dallos V, Heathfield K, Stone P, Allen FA. Use of amantadine in Parkinson's disease. Results of a double‐blind trial. British Medical Journal 1970;4(726):24‐26. - PMC - PubMed
Dallos 1972 {published data only}
    1. Dallos V, Heathfield K, Stone P, Allen F. The comparative value of amantadine and levodopa. Postgraduate Medical Journal 1972;48(560):354‐358. - PMC - PubMed
Evidente 1999 {published data only}
    1. Evidente VGH, Adler CH, Caviness JN, Gwinn‐Hardy K. A pilot study on the motor effects of Rimantadine in Parkinson's disease. Clinical Neuropharmacology 1999;22(1):30‐32. - PubMed
Fehling 1972 {published data only}
    1. Fehling C. Administration of amantadine to patients on optimum L‐dopa dosage. Acta Neurologica Scandinavica 1972;51(Supplement):119‐120. - PubMed
Fieschi 1970a {published data only}
    1. Fieschi C, Nardini M, Casacchia M, Tedone ME. Amantadine for Parkinson's disease. Lancet 1970;1(7653):945‐946. - PubMed
Fieschi 1970b {published data only}
    1. Fieschi C, Nardini M, Casacchia M, Tedone ME, Reitano M, Robotti E. Amantadine versus L‐2 dopa and amantadine plus L‐dopa. Lancet 1970;2(7664):154‐155. - PubMed
Fieschi 1970c {published data only}
    1. Fieschi C, Nardini M, Casacchia M, Reitano M, Tedone M E, Ferrari P, Robotti E. Drug therapy of Parkinson's disease with amantadine and levodopa [Terapia farmacologica della malattia di Parkinson con amantadina e levodopa]. Sistema Nervoso 1970;22(2):126‐143. - PubMed
Fischer 1977 {published data only}
    1. Fischer VPA, Jacobi P, Schneider E, Schonberger B. Effects of intravenous administration of memantine in Parkinsonian patients [Die wirkung intravenoser gaben von memantin bei Parkinson‐kranken]. Arzneimittel‐Forschung / Drug Research 1977;27(II):1487‐1489. - PubMed
Forssman 1972 {published data only}
    1. Forssman B, Kihlstrand S, Larsson LE. Amantadine therapy in parkinsonism. Acta Neurologica Scandinavica 1972;48(1):1‐18. - PubMed
Freedman 1971 {published data only}
    1. Freedman BE, Getz E, MacGregor JM, Ames FR. Amantadine hydrochloride in the treatment of parkinsonism: a placebo‐controlled double‐blind study. South African Medical Journal 1971;45(16):435‐437. - PubMed
Funfgeld 1970 {published data only}
    1. Funfgeld EW. The effect of amantadine in parkinsonism: clinical and neurophysiological findings [Amantadin‐Wirkung bei Parkinsonismus: klinik und neurophysiologie]. Deutsche Medizinische Wochenschrift 1970;95(36):1834‐1836. - PubMed
Getz 1970 {published data only}
    1. Getz R. Symmetrel in Parkinson's disease. South African Medical Journal 1970;44:955‐956. - PubMed
Gilligan 1970 {published data only}
    1. Gilligan BS, Veale J, Wodak J. Amantadine hydrochloride in the treatment of Parkinson's disease. Medical Journal of Australia 1970;2(14):634‐637. - PubMed
Godwin‐Austen 1970 {published data only}
    1. Godwin‐Austen RB, Frears CC, Bergmann S, Parkes JD, Knill‐Jones RP. Combined treatment of parkinsonism with L‐dopa and amantadine. Lancet 1970;2(7669):383‐385. - PubMed
Griffiths 1971 {published data only}
    1. Griffiths AV, Parker WN, Palmer RM. Experiences with amantadine hydrochloride in Parkinson's disease. Practitioner 1971;207(241):679‐680. - PubMed
Hacohen 1972 {published data only}
    1. Hacohen H, Gurtner B. [Klinische prufung des therapieeffektes von amanatine‐HCl bei morbus Parkinson]. Schweizer Medizinische Wochenschrift 1972;102(16):583‐586. - PubMed
Hueber 1996 {published data only}
    1. Hueber R. Efficacy and tolerability of amantadine sulfate in the treatment of Parkinson's disease [Wirksamkeit und Vertraglichkeit von Amantadinsulfat in der Behandlung des Morbus Parkinson]. Medizinische Welt 1996;47(2):79‐84.
Hunter 1970a {published data only}
    1. Hunter KR, Stern GM, Laurence DR, Armitage P. Amantadine in parkinsonism. Lancet 1970;7657(1127‐1129). - PubMed
Hunter 1970b {published data only}
    1. Hunter KR, Stern GM, Laurence DR, Armitage P. Combined treatment of parkinsonism with L‐dopa and amantadine. Lancet 1970;2(7672):566. - PubMed
Iivanainen 1974 {published data only}
    1. Iivanainen M. Kr339 in the treatment of Parkinsonianisms [Kr339 Parkinsonismivapian Hoidossa]. Duodecim 1974;99:590‐596. - PubMed
Iizuka 1986 {published data only}
    1. Iizuka J, Fischer R. Modification of Parkinsonian tremor by budipine. A comparative study with amantadine. [Beeinflussung des Parkinson‐tremors durch budipin. Eine vergleichsstudie mit amantadine.]. Der Nervenartz 1986;57(3):184‐186. - PubMed
Jorgensen 1971 {published data only}
    1. Jorgensen PB, Bergin JD, Haas L, Cuningham JA, Morah DD, Pollock M, Robinson RG, Spears GF. Controlled trial of amantadine hydrochloride in Parkinson's disease. New Zealand Medical Journal 1971;73(468):263‐267. - PubMed
Kiseleva 1973 {published data only}
    1. Kiseleva A M, et al. The therapeutic effectiveness of amantadine in Parkinsonism syndromes [(In Russian)]. Zhurnal Neuropathologii I Psikhiatmi Imen I S.S Korsakova 1973;73(4):530‐534. - PubMed
Laitinen 1971 {published data only}
    1. Laitinen LV, Vilkki J. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study. Annals of Clinical Research 1971;3(4):207‐211. - PubMed
MacFadyen 1972 {published data only}
    1. MacFadyen DJ, Picton TW, Zeldowicz L, McGeer PL. Amantadine‐HCl in the treatment of Parkinson's disease: a controlled trial. The Journal of Clinical Pharmacology: New Drugs 1972;12(7):274‐279. - PubMed
Malsch 2001 {published data only}
    1. Malsch U, Bliesath H, Bother K, Ramm H, Luhmann R. Monotherapy of Parkinson's disease with budipine ‐ A randomised double‐blind comparison to amantadine [Monotherapie der Parkinsonschen erkrankung mit budipin ‐ Ein randomisierter doppelblindvergleich mit amantadin]. Fortschritte der Neurologie, Psychiatre und ihrer Grenzgebiete 2001;69(2):86‐89. - PubMed
Mann 1971 {published data only}
    1. Mann DC, Pearce LA, Waterbury LD. Amantadine for Parkinson's disease. Neurology 1971;21(9):958‐962. - PubMed
Matsumoto 1974 {published data only}
    1. Matsumoto K, Omoto T, Beck H. Clinical evaluation of amantadine therapy for parkinsonism and the side effect ‐ in cases of thalamic surgery and L‐dopa therapy. Folia Psychiatrica et Neurologica Japonica 1974;28(1):1‐10. - PubMed
Mawdsley 1972 {published data only}
    1. Mawdsley C, Williams IR, Pullar IA, Davidson DL, Kinloch NE. Treatment of parkinsonism by amantadine and levodopa. Clinical and Pharmacological Therapies 1972;13(4):575‐583. - PubMed
Merello 1999 {published data only}
    1. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double‐blind cross‐over randomized study. Clinical Neuropharmacology 1999;22(5):273‐276. - PubMed
Merrick 1973 {published data only}
    1. Merrick EM, Schmitt PP. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Current Therapeutic Research, Clinical and Experimental 1973;15(8):552‐558. - PubMed
Merry 1974 {published data only}
    1. Merry RTG, Galbraith AW. A double blind study of Symmetrel (amantadine hydrochloride) in Parkinson's disease. Journal of International Medical Research 1974;2(2):137‐141.
Millac 1970 {published data only}
    1. Millac P, Hasan I, Espir ML, Slyfield DG. Treatment of Parkinsonism with L‐dopa and amantadine. Lancet 1970;2(7675):720. - PubMed
Muschard 1973 {published data only}
    1. Muschard F, Voller GW. Efficacy of amantadine sulfate as a infusion solution in the treatment of parkinsonian syndrome [Wirksamkeit von amantadinsulfat als infusionslosun bei der behandlung des Parkinson‐syndroms]. Medizinische Welt 1973;24(5):183‐184. - PubMed
Parkes 1970a {published data only}
    1. Parkes JD, Calver DM, Zilkha KJ, Knill‐Jones RP. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970;1(7641):259‐262. - PubMed
Parkes 1970b {published data only}
    1. Parkes JD, Zilkha KJ, Marsden P, Baxter RC, Knill‐Jones RP. Amantadine dosage in treatment of Parkinson's disease. Lancet 1970;1(7657):1130‐1133. - PubMed
Parkes 1971a {published data only}
    1. Parkes JD, Zilkha KJ, Knill‐Jones RP, Clements PJ, Baxter R. L‐dopa and amantadine hydrochloride in Parkinson's disease. Internationale Zeitschrift fur Klinische Pharmakologie Therapie und Toxikologie 1971;4(3):356‐360. - PubMed
Parkes 1971b {published data only}
    1. Parkes JD, Baxter RC, Curzon G, Knill‐Jones RP. Treatment of Parkinson's disease with amantadine and levodopa. A one‐year study. Lancet 1971;1:1083‐1086. - PubMed
Parkes 1974 {published data only}
    1. Parkes, JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1974;37(4):422‐426. - PMC - PubMed
Pendefunda 1975 {published data only}
    1. Pendefunda G, Pollingher B, Stefanache F, Gavril A, Oprisan C, Merling M, Nemteanu E, Ciunru M, Koropitzer I. The treatment with L‐dopa and amantadine in Parkinson's disease. Therapia Hungarica 1975;23(1):12‐16. - PubMed
Pollock 1972 {published data only}
    1. Pollock M, Jorgensen PB. Combined L‐dopa and amantadine in Parkinsonism. Australia and New Zealand Journal of Medicine 1972;2(3):252‐255. - PubMed
Rao 1971 {published data only}
    1. Rao NS, Pearce J. Amantadine in Parkinsonism. An extended prospective trial. Practitioner 1971;206(232):241‐245. - PubMed
Reveno 1971 {published data only}
    1. Reveno WS, Bauer RB, Rosenbaum H. L‐dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride. Geriatrics 1971;26(8):61‐70. - PubMed
Rinne 1972 {published data only}
    1. Rinne UK, Sonninen V, Siirtola T. Treatment of Parkinson's disease with amantadine and L‐dopa. European Neurololgy 1972;7(4):228‐240. - PubMed
Sandyk 1981 {published data only}
    1. Sandyk R. Latency and successive reaction time in Parkinson's disease ‐ the effects of carbidopa and amantadine. South African Medical Journal 1981;59(13):441. - PubMed
Savery 1976 {published data only}
    1. Savery F. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report. Current Therapeutic Research, Clinical and Experimental 1976;19(3):337‐338. - PubMed
Schneider 1984 {published data only}
    1. Schneider E, Fischer PA, Clemens R, Balzereit F, Funfgeld EW, Haase HJ. Effects of oral memantine on symptoms of Parkinson's disease [Wirkungen oraler memantin‐gaben auf die Parkinson‐symptomatik]. Deutsche Medizinische Wochenschrift 1984;109(25):987‐990. - PubMed
Schwab 1969a {published data only}
    1. Schwab RS, England AC. Amantadine HCL (Symmetrel) and its relation to Levo‐Dopa in the treatment of Parkinson's disease. Transmissions of the American Neurological Association 1969;94:85‐90. - PubMed
Schwab 1969b {published data only}
    1. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. Journal of the American Medical Association 1969;208:1168‐1170. - PubMed
Schwieger 1970 {published data only}
    1. Schwieger AC, Jenkins AC. Observations on the effect of amantadine hydrochloride in the treatment of Parkinsonism. Medical Journal of Australia 1970;2:630‐632. - PubMed
Shiozawa 1974 {published data only}
    1. Shiozawa R, Hirayama K, Ishizima B, Itoh H, Maruyama S, Hirotaro N, Takahashi R, Uono M, Yoshida M. Treatment of Parkinson's disease with Amantadine‐HCl (Symmetrel) and trihexypheidyl: Double‐blind controlled trial.. Advances in Neurological Science 1974;18(5):949‐960.
Shiozawa 1981 {published data only}
    1. Shiozawa R, Kase M, Kuroiwa Y, Narabayashi H, Nishitani Y, Ohmoto T, Tokokura Y, Uono K. The additive effect of amantadine hydrochlorise on Parkinsonian patients recieving levodopa treatment [(In Japanese)]. No To Shinkei 1981;33(3):301‐309. - PubMed
Sigwald 1970 {published data only}
    1. Sigwald J, Raymondeaud C, Piot C. Results of two new drugs in Parkinson's disease: L‐dopa and amantadine. Rev Neurologie (Paris) 1970;122(2):145‐148. - PubMed
Sigwald 1972 {published data only}
    1. Sigwald J, Raymondeaud Cl, Gregoire J. Treatment of Parkinson's disease with amantadine [Le traitement de la maladie de Parkinson par l'amatadine]. Therapeutique 1972;48(9):555‐560. - PubMed
Timberlake 1978 {published data only}
    1. Timberlake WH, Vance MA. Four‐year treatment of patients with parkinsonism using amantadine alone or with levodopa. Annals of Neurology 1978;3(2):119‐128. - PubMed
Voller 1973 {published data only}
    1. Voller GW, Deze J. Therapeutic experiences with amantadine sulfate as a monotherapeutic drug in patients with Parkinsonism [Therapeutische erfahrungen mit amantadinsulfat als medikamentoses monotherapeutikum bei Parkinsonkraken]. Zeitschrift fur Allgemeinmedizin 1973;49(14):664‐670. - PubMed
Webster 1984 {published data only}
    1. Webster DD, Sawyer GT. The combined use of amantadine HC1 and levodopa/carbidopa in Parkinson's disease. Current Therapeutic Research, Clinical and Experimental 1984;35(6):1010‐1013.
Weeth 1969 {published data only}
    1. Weeth JB, Shealy CN, Mercier DA. L‐dopa and amantadine in the therapy of parkinsonism. Wisconsin Medical Journal 1969;68(11):325‐328. - PubMed
Zeldowicz 1973 {published data only}
    1. Zeldowicz LR, Huberman J. Long‐term therapy of Parkinson's disease with amantadine, alone and combined with levodopa. Canadian Medical Association Journal 1973;109:588‐593. - PMC - PubMed

References to studies awaiting assessment

Hakkarainen 1973 {published data only}
    1. Hakkarainen H, Viukari M. Amantadine and dexetimide in the treatment of Parkinsonism [Amantadiini ja deksetimidi Parkinsonismin hoidossa]. Duodecim 1973;89(21):1437‐1441. - PubMed

Additional references

CONSORT 2001
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. The Lancet 2001;357:1191‐1194. - PubMed
Crosby 2002
    1. Crosby NJ, Deane KHO, Clarke CE. Amantadine for dyskinesia in Parkinson's disease (Cochrane review). The Cochrane Library 2002, Issue 2. - PMC - PubMed
Hughes 1992
    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico‐pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992;3:181‐184. - PMC - PubMed
Kornhuber 1994
    1. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. Journal of Neural Transmission 1994;43:91‐104. - PubMed
Mizoguchi 1994
    1. Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re‐uptake inhibition and by N‐methyl‐D‐aspartate antagonism. Brain Research 1994;662(1‐2):255‐258. - PubMed
Quinn 1986
    1. Quinn N, Critchley P, Parkes D, Marsden CD. When should levodopa be started?. Lancet 1986;ii:985‐986. - PubMed
Rajput 1984
    1. Rajput AH, Stern W, Laverty WH. Chronic low‐dose levodopa therapy in Parkinson's disease. Neurology 1984;34:991‐996. - PubMed
Takahashi 1996
    1. Takahashi T, Yamashita H, Zhang Y, Nakamura S. Inhibitory effect of MK‐801 on amantadine‐induced dopamine release in the rat striatum. Brain Research Bulletin 1996;41(6):363‐367. - PubMed

Publication types

MeSH terms